Assessing the safety of deferoxamine mesylate after intracerebral hemorrhage: a futility analysis

Takeaway

  • Treating patients with the iron chelator deferoxamine mesylate (DFO) for three consecutive days after intracerebral hemorrhage (ICH) is safe, however it would be futile to further investigate the drug’s efficacy in a large phase 3 clinical trial in patients demonstrating good clinical outcome at 90 days.

Why this matters

  • Iron is released from hemoglobin degradation products after red blood cell hemolysiswhich results in secondary neuronal injury after ICH, and evidence suggests a neuroprotective role for DFO.

  • This study reveals crucial implications for designing future clinical trials for investigating DFO in patients with ICH, which will enable to specifically target iron-mediated toxicity and secondary injury to improve patient outcomes.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.